Recombinant human tumor necrosis factor-α covalently conjugated to long-circulating liposomes

International Journal of Pharmaceutics

Volumn 131, Issue 1, 1996, Pages 57-66

  Mori, Atsuhide ^a,c   Duda, Ernó ^b   Huang, Leaf ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biodistribution; Drug delivery; Long circulating liposome; Recombinant tumor necrosis factor (rHuTNF)

Indexed keywords

CHOLESTEROL; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN L 929; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; ENCAPSULATION; FEMALE; FIBROBLAST; INTRAVENOUS DRUG ADMINISTRATION; LIPID COMPOSITION; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0029863821     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04304-7     Document Type: Article

References (27)

1. Alving, C.R., Delivery of liposome-encapsulated drugs to macrophages. In: Ihler, G.M. (Ed.), Methods of Drug Delivery, Pergamon, Oxford, 1986, pp. 281-300.
2. Debs, R.J., Duzgunes, N., Brunette, E.N., Fendly, B., Patton, J. and Philip, R., Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing antitumor necrosis factor antibodies. J. Immunol., 143 (1989) 1192-1197.
3. Debs, R.J., Fuchs, H.J., Philip, R., Brunette, E.N., Duzgunes, N., Shellito, J.E. and Liggitt, D., Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor α in rats. Cancer Res., 50 (1990) 375-380.
4. Ferraiolo, B.L., Moore, J.A., Crase, D., Gribling, P., Wilking, H. and Baughman, R.A., Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-α in mice. Drug Metab. Dispos., 16 (1988) 270-275.
5. Ferraiolo, B.L., McCabe, J., Hollenbach, S., Hultgren, B., Pitti, R. and Wilking, H., Pharmacokinetics of recombinant human tumor necrosis factor-α in rats: Effects of size and number of doses and nephrectomy. Drug Metab. Dispos., 17 (1989) 369-372.
6. Fiers, W., Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett., 285 (1991) 199-212.
7. Gabizon, A. and Papahadjopoulos, D., Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA, 85 (1988) 6949-6953.
8. Kabalka, G., Buonocore, E., Hubner, K., Moss, T., Norley, N. and Huang, L., Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology, 163 (1987) 255-258.
9. Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P. and Huang, L., Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta, 1062 (1991) 142-148.
10. Klibanov, A.L. and Huang, L. Long-circulating liposomes: development and perspectives. J. Liposome Res., 2 (1992) 321-334.
11. Lasic, D.D., Liposomes: From Physics to Applications. Elsevier Science Publishers, New York, 1993.
12. Maruyama, K., Mori, A., Bhadra, S., Subbiah, M.T.R. and Huang, L., Proteins and peptides bound to long-circulating liposomes. Biochim. Biophys. Acta, 1070 (1991) 246-252.
13. McMartin, C., Pharmacokinetics of peptides and proteins: opportunities and challenges. Adv. Drug Res., 22 (1992) 39-106.
14. M1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett., 284 (1991) 263-266.
15. Nii, A., Fan, D. and Fidler, I.J., Cytotoxic potential of liposomes containing tumor necrosis factor-α against sensitive and resistant target cells. J. Immunol., 10 (1991) 13-19.
16. Pacici, A., Maioli, E., Bocci, V. and Pessina, G.P., Studies on tumor necrosis factor (TNF). III. Plasma disappearance curves after intramuscular, subcutaneous, intraperitoneal, and oral administration of human recombinant TNF. Cancer Drug Delivery, 4 (1987) 17-23.
17. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.-D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, F.J., Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci., 88 (1991) 11460-11464.
18. Pennica, D., Nedwin, G.E., Hayflick, J.S., Seeburg, P.H., Derynck, R., Palladino, M.A., Kohr, W.J., Aggarwal, B.B. and Goeddel, D.V., Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature, 312 (1984) 724-729.
19. Porter, A.G., The prospects for therapy with tumour necrosis factors and their antagonists. TIBTECH, 9 (1991) 158-162.
20. Ruff, M.R. and Gifford, G.E., Tumor necrosis factor. In: E. Pick (Ed.), Lymphokines, Academic Press, New York, 1981, pp. 235-272.
21. Sidhu, R.S. and Bollon, A.P., Tumor necrosis factor activities and cancer therapy-a perspective. Pharm. Ther., 57 (1992) 79-128.
22. Spriggs, D.R. and Yates, S.W., Cancer chemotherapy: experiences with TNF administration in humans. In: B. Beutler (ed.). Tumor Necrosis Factor: The Molecules and Their Emerging Role in Medicine, New York: Raven Press, 1992, pp. 383-406.
23. M1-bearing long-circulating liposomes. J. Drug Targeting, 1 (1993) 287-292.
24. Utsumi, T., Hung, M.-C. and Klostergaard, J., Preparation and characterization of liposomal-lipophilic tumor necrosis factor. Cancer Res., 51 (1991) 3362-3366.
25. Woodle, M.C., Storm, G., Newman, M.S., Jekot, J.J., Collins, L.R., Martin, F.J. and Szoka, F.C., Jr., Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharm. Res., 9 (1992) 260-265.
26. Woodle, M.C. and Lasic, D.D., Sterically stabilized liposomes. Biochim. Biophys. Acta, 1113 (1992) 171-199.
27. Wu, M.S., Robbins, J.C., Bugianesi, R.L., Ponpipom, M.M. and Shen, T.Y., Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim. Biophys. Acta, 674 (1981) 19-29.